Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Army
Colorcon
Moodys
Healthtrust
McKinsey
Federal Trade Commission
Covington
McKesson
Citi

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,294,540

« Back to Dashboard

Which drugs does patent 6,294,540 protect, and when does it expire?

Patent 6,294,540 protects ZIAGEN, EPZICOM, TRIUMEQ, and TRIZIVIR, and is included in five NDAs.

Protection for ZIAGEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-nine patent family members in forty-eight countries.
Summary for Patent: 6,294,540
Title: Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Abstract:The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Inventor(s): Brodie; Alastair Couper (London, GB), Jones; Martin Francis (Kneloworth, GB), Seager; John Frederick (Ware, GB), Wallis; Christopher John (Rayston, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/423,982
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 6,294,540

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Viiv Hlthcare ZIAGEN abacavir sulfate SOLUTION;ORAL 020978-001 Dec 17, 1998 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare ZIAGEN abacavir sulfate TABLET;ORAL 020977-001 Dec 17, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,294,540

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9709945May 17, 1997
PCT Information
PCT FiledMay 14, 1998PCT Application Number:PCT/EP98/02835
PCT Publication Date:November 26, 1998PCT Publication Number: WO98/52949

International Patents Family Members for US Patent 6,294,540

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia 285159 ➤ Sign Up
Slovakia 156199 ➤ Sign Up
Slovenia 0983271 ➤ Sign Up
Saudi Arabia 1122 ➤ Sign Up
Serbia 49655 ➤ Sign Up
Portugal 983271 ➤ Sign Up
Poland 189527 ➤ Sign Up
Poland 336888 ➤ Sign Up
Peru 78799 ➤ Sign Up
Peru 74799 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Deloitte
US Department of Justice
Express Scripts
QuintilesIMS
Chubb
Fish and Richardson
Harvard Business School
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot